The United States Food and Drug Administration (FDA) has approved the first novel coronavirus (COVID-19) treatment for young children aged 28 days and older. FDA notes that the treatment is for such children who are:
- Hospitalized, or
- Not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.
To read the FDA announcement and summary of its approval of the first COVID-19 treatment for young children, use the link below.